FDA 483 - Janssen Biotech, Inc - September 27, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Janssen Biotech, Inc. in Titusville, NJ, was cited for failing to comply with the audit plan and schedule outlined in its approved Risk Evaluation and Mitigation Strategy (REMS) Implementation System. The inspection revealed that initial and subsequent audits for authorized distributors and certified pharmacies, including those handling Tecvayli or Talvey, were not completed by their due dates. This indicates a significant lapse in adhering to established risk management protocols.
ID · b0f75aa3-e5bb-4f56-ba6c-c8f44f8c2da1